Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
Immunotherapy combined with chemotherapy can provide a survival benefit, and the addition of immunotherapy does not result in significant toxicity in elderly patients. The results of this study have important clinical implications for the future treatment of elderly patients with ES-SCLC.
Authors
- Shuangqing Lu
- Hui Zhu (ORCID: https://orcid.org/0000-0002-2001-6312)
- Ke‐Qing Zhao (ORCID: https://orcid.org/0000-0001-5703-3768)
- Jinming Yu (ORCID: https://orcid.org/0000-0001-5933-9912)
- Yaru Tian (ORCID: https://orcid.org/0009-0000-5962-6890)
- Jiling Niu
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1186/s12885-025-13880-z
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province